Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT04670172
Recruiting Observational

Real-Life Chronic Rhinosinusitis Outcome Registry

NCT04670172 · tracked via the Priya Life Science Italy tracker
Sponsor
Change Accelerator in Respiratory Care
Phase
Observational
Started
2021-01-01
Last updated
2025-02-13

Condition(s) studied

Chronic Rhinosinusitis (Diagnosis)

Study summary

An international consortium of leading medical experts in the field of chronic respiratory disease, the research team of Galenus Health and the non-profit organization EUFOREA (European Forum for Research and Education in Allergy and Airway diseases) has been conceived to conduct real-life outcome research. The Galenus Health digital platform consisting of a mobile application for patients and an online dashboard for physicians will be implemented in each of the participating centres. The data will be centralized in a pseudonymized database and will be the basis of the Chronic RhinoSinusitis Outcome Registry.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Physician diagnosis of Chronic RhinoSinusitis * Capable of using a mobile application on a smartphone Exclusion Criteria: * Patients with malignancies of the sinonasal cavity * Patients with inverted papilloma * Patients with unilateral disease

Primary outcome measure(s)

  • Symptom severity total symptoms — 1 year
    Baseline and change in VAS (visual analogue scale) total nasal, sinus, lung symptoms; 0 (Not at all bothersome) - 100 (Extremely bothersome) mm

Trial sites (13)

FacilityCityRegionStatus
Graz University Hospital Graz Austria Recruiting
University Hospital Vienna Vienna Austria Recruiting
UCL Saint-Luc Brussels Belgium Recruiting
UZ Ghent Ghent Belgium Recruiting
UZ Leuven Leuven Belgium Recruiting
Odense University Hospital Odense Denmark Recruiting
Helsinki University Hospital Helsinki Finland Not Yet Recruiting
CHU Lille Lille France Recruiting
Dusseldorf University Clinic Düsseldorf Germany Recruiting
Policlinico Umberto I Rome Italy Recruiting
UMC Amsterdam Amsterdam Netherlands Recruiting
Hospital Clinic de Barcelona Barcelona Spain Recruiting
Prof Claire Hopkins private practice London United Kingdom Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04670172 on ClinicalTrials.gov ↗ ← All trials in Italy